At Sonnet BioTherapeutics, we are developing targeted immuno-oncology drugs that turn ‘cold’ tumors ‘hot’. Our proprietary FHAB™ (Fully Human Albumin-Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.
About Sonnet BioTherapeuticsOur modular FHAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.
Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
Technology Platform
Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates.
Pipeline
The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.
TeamStay informed and receive company updates straight to your inbox.
